A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors

Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents

(2013) Yingjie Zhang et al.   Anti-Cancer Agents in Medicinal Chemistry

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

(2008) S P Blagden et al.   BRITISH JOURNAL OF CANCER

Microtubule dynamics as a target in oncology

(2008) April L. Risinger et al.   CANCER TREATMENT REVIEWS

Microtubule Active Agents: Beyond the Taxane Frontier

(2008) P. G. Morris et al.   CLINICAL CANCER RESEARCH

Southwest Oncology Group Phase II Study of Ispinesib in Androgen-Independent Prostate Cancer Previously Treated with Taxanes

(2008) Tomasz M. Beer et al.   Clinical Genitourinary Cancer

Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer

(2008) Christopher D. Cox et al.   JOURNAL OF MEDICINAL CHEMISTRY